Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 12/20 | 0.71 |
| ▸ | HTR2C | P28335 | 12/20 | 0.71 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.48 |
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | HTR5A | P47898 | 1/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6713978 | 0.92 | HTR2A (0.71) | HTR2AHTR2CHTR3EHTR3BHTR3A | |
| SCHEMBL6711322 | 0.90 | HTR2A (0.68) | HTR2AHTR2CHTR3EHTR3BHTR3A | |
| SCHEMBL6711152 | 0.84 | HTR2A (1.00) | HTR2AHTR2CHTR3EHTR3BHTR3A | |
| SCHEMBL29391845 | 0.84 | HTR2A (1.00) | HTR2AHTR2CHTR3EHTR3BHTR3A | |
| SCHEMBL6719341 | 0.83 | HTR2A (0.58) | HTR2AHTR2CHTR3AHTR5AHTR1A | |
| SCHEMBL6713608 | 0.83 | HTR2A (0.58) | HTR2AHTR2CHTR3ASLC6A4HTR1A | |
| SCHEMBL6711196 | 0.83 | HTR2C (0.59) | HTR2AHTR2CHTR3EHTR3BHTR3A | |
| SCHEMBL6711371 | 0.83 | HTR2A (0.55) | HTR2AHTR2CHTR3EHTR3BHTR3A | |
| SCHEMBL6715702 | 0.83 | HTR2A (0.62) | HTR2AHTR2CHTR3EHTR3BHTR3A | |
| SCHEMBL6713998 | 0.83 | HTR2C (0.58) | HTR2AHTR2CHTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209870-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | ENNIS MICHAEL DALTON (US) | 2004-10-21 | — | — | US | claimed |
| US-6734301-B2 | 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2004-05-11 | — | — | US | claimed |
| EP-1328525-A2 | 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-A]INDOLE COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-23 | — | — | EP | claimed |
| US-20020002161-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | PHARMACIA & UPJOHN COMPANY | 2002-01-03 | — | — | US | claimed |
| WO-2001072752-A2 | 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-04 | — | — | WO | claimed |
| US-20040209870-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | ENNIS MICHAEL DALTON (US) | 2004-10-21 | — | — | US | disclosed |
| US-6734301-B2 | 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2004-05-11 | — | — | US | disclosed |
| EP-1328525-A2 | 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-A]INDOLE COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20020002161-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | PHARMACIA & UPJOHN COMPANY | 2002-01-03 | — | — | US | disclosed |
| WO-2001072752-A2 | 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS | PHARMACIA & UPJOHN COMPANY (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002161-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | HTR1D, HTR1A, HTR1E | HTR2A 18/4885HTR2C 7/4885HTR3E 13/4885 |
| US-20040209870-A1 | Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds | HCRTR2, NR2C2, RCOR3 | HTR2A 1403/4885HTR2C 553/4885HTR3E 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.